Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega 3-6 fatty acids in children with ASD
NCT03550209Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) (4 arms). Primary endpoints: Bioavailability at 90 days, Safety (Adverse Events) at 90 days and 1 more. Started Jun 2018; status: completed.
02
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03550209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550209.